Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (111-120 of 227) with videos related to

Pageof 23
Sort By:
Journal of the American Heart Association|July 24, 2018
Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 TrialGilles R Dagenais, Hyejung Jung, Eva Lonn, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
European Heart Journal|February 28, 2016
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillationZiad Hijazi, Johan Lindbäck, John H Alexander, et al.
Journal of the American Heart Association|October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialClaes Held, Harvey D White, Ralph A H Stewart, et al.
American Heart Journal|April 30, 2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndromeNeha J Pagidipati, Connie N Hess, Robert M Clare, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
American Heart Journal|September 11, 2013
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trialEmmanouil S Brilakis, Claes Held, Bernhard Meier, et al.
ESC Heart Failure|July 9, 2025
Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classificationVeraprapas Kittipibul, Harriette G C Van Spall, William Schuyler Jones, et al.
Pageof 23

Showing results (111-120 of 227) with videos related to

Sort By:
Pageof 23
Journal of the American Heart Association|July 24, 2018
Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 TrialGilles R Dagenais, Hyejung Jung, Eva Lonn, et al.
Journal of the American College of Cardiology|March 25, 2014
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesElaine M Hylek, Claes Held, John H Alexander, et al.
European Heart Journal|February 28, 2016
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillationZiad Hijazi, Johan Lindbäck, John H Alexander, et al.
Journal of the American Heart Association|October 26, 2017
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialClaes Held, Harvey D White, Ralph A H Stewart, et al.
American Heart Journal|April 30, 2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndromeNeha J Pagidipati, Connie N Hess, Robert M Clare, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
American Heart Journal|September 11, 2013
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trialEmmanouil S Brilakis, Claes Held, Bernhard Meier, et al.
ESC Heart Failure|July 9, 2025
Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classificationVeraprapas Kittipibul, Harriette G C Van Spall, William Schuyler Jones, et al.
Pageof 23